Skip to main content

NERV

Stock
Health Care
Biotechnology

Performance overview

NERV Price
Price Chart

Forward-looking statistics

Beta
1.24
Risk
77.99%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Company info

SectorHealth Care
IndustryBiotechnology
Employees8
Market cap$22.5M

Fundamentals

Enterprise value$54.7M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity-2.06

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.82
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$23K
Avg trading volume (10 day)$11K
Put-call ratio

Macro factor sensitivity

Growth-4.8
Credit+6.9
Liquidity+4.6
Inflation-10.7
Commodities-6.5
Interest Rates-1.8

Valuation

Dividend yield0.00%
PEG Ratio-0.62
Price to sales
P/E Ratio-0.62
Enterprise Value to Revenue
Price to book-0.43

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock?

Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (May 6, 2024)
Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

Minerva Neurosciences Inc (NASDAQ: NERV) received the official meeting minutes from the Type C meeting with the FDA regarding the development of roluperidone for negative symptoms in schizophrenia. The agency cited concerns related to the applicability of the results of the Phase 2b.

Benzinga (April 7, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free